In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med (RMTI), with a price target of $5.50. The company’s shares closed last Friday at $1.37.
According to TipRanks.com, Selvaraju is a top 25 analyst with an average return of 52.7% and a 82.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, NeuroBo Pharmaceuticals, and Inovio Pharmaceuticals.
Rockwell Med has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
See today’s analyst top recommended stocks >>
Rockwell Med’s market cap is currently $128.2M and has a P/E ratio of -3.20. The company has a Price to Book ratio of 3.12.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rockwell Medical, Inc. engages in targeting end-stage renal disease and chronic kidney disease. Its dialysis products include hemodialysis concentrates, citrapure, dri-sate, safety data sheets,ancillary products, and renal pure. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.
